NL-OMON51348已完成不适用
A study of the effects of single doses of MK-1167 on neurotransmitter cycling in the brain of healthy adult participants using 13C-Magnetic Resonance Spectroscopy. - MK-1167 Effect on Neurotransmitter Cycling in Healthy Participants
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co. Inc.0 个研究点目标入组 48 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •Body Mass Index (BMI) between >= 18 and <=30 kg/m2, inclusive
- •Be judged to be in good health based on medical history, physical and
- •neurological examination, VS measures, ECGs and laboratory safety tests
- •obtained at the screening visit.
- •Participants should be male, from 18 years to 60 years of age inclusive at the
- •time of providing informed consent.
排除标准
- •History of clinical signifiant endocrine, GI, cardiovasculair, hematological,
- •hepatic, immunological, renal, respiratory, genitourinary, or major
- •neurological (including stroke and chronic seizures) abnormalities or diseases.
- •Participants with a remote history of uncomplicated medical events (eg,
- •uncomplicated kidney stones, as defined as spontaneous passage and no
- •recurrence in the last 5 years, or childhood asthma) may be enrolled in the
- •study at the discretion of the investigator.
- •Mentally or legally incapacitated, has significant emotional problems at the
- •time of screening visit or expected during the conduct of the study or has a
- •history of clinically significant psychiatric disorder in the last 5 years.
- •Participants who have had situational depression may be enrolled in the study
- •at the discretion of the investigator.
- •Further criteria apply, see protocol.
研究者
相似试验
进行中（未招募）
1 期
A Dose-Ranging Study of the Effects of SCH 527123 in Subjects With Moderate to Severe COPDCOPDMedDRA version: 9.1 Level: LLT Classification code 10009033 Term: Chronic obstructive pulmonary diseaseEUCTR2008-003780-38-FRSchering-Plough Research Institute500
招募中
2 期
A Dose-Ranging Study of the Effects of SCH 527123 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)ACTRN12610000345088Schering-Plough500
进行中（未招募）
1 期
A Dose-Ranging Study of the Effects of SCH 527123 in Subjects With Moderate to Severe COPD - NDCOPDMedDRA version: 9.1 Level: PT Classification code 10009033EUCTR2008-003780-38-ITSchering Plough Research Institute500
进行中（未招募）
1 期
A Dose-Ranging Study of the Effects of SCH 527123 in Subjects With Moderate to Severe COPDCOPDMedDRA version: 9.1 Level: LLT Classification code 10009033 Term: Chronic obstructive pulmonary diseaseEUCTR2008-003780-38-GRSchering-Plough Research Institute500
未知
1 期
Clinical pharmacology study of K-877DyslipidemiaJPRN-jRCT2080222359Kowa Co., Ltd.32